Strand Therapeutics

Strand Therapeutics. It is a privately held biotechnology company pioneering the development of programmable messenger RNA (mRNA) therapies for oncology and other diseases. Founded in 2017, the company leverages synthetic biology to create mRNA molecules that can sense their cellular environment and make logic-guided decisions. Its platform aims to deliver more precise, effective, and safer treatments compared to conventional mRNA technologies.

History

The company was founded in 2017 by Jake Becraft and Tasuku Kitada, who met as graduate researchers at the Massachusetts Institute of Technology. Their work originated within the MIT Synthetic Biology Center, building upon foundational research in genetic circuits and RNA biology. Initial technology development was supported by grants from the National Science Foundation and the National Institutes of Health. The company emerged from stealth mode in 2019, announcing a seed financing round led by Playground Global to advance its programmable mRNA platform. Early research operations were conducted in Cambridge, Massachusetts, before the company established its headquarters in the Seaport District of Boston.

Technology

The core innovation is a platform for creating logic-gated, programmable mRNA therapeutics. Unlike conventional mRNA approaches used in COVID-19 vaccines, which cause cells to constitutively produce a protein, Strand's technology uses engineered mRNA sequences that function as biological computers. These molecules can be designed to activate only in specific target cell types, such as tumor cells, while remaining inactive in healthy tissues. The platform utilizes proprietary 5' untranslated region (5' UTR) designs and cis-regulatory elements that respond to intracellular signals. This approach allows for multi-input sensing, enabling therapeutic protein expression based on the presence of specific microRNA profiles or other biomarkers found in diseased cells. The technology is applied to develop immunotherapies, including cytokine-based treatments and CAR-expressing therapies.

Clinical development

The company's lead candidate, STX-001, is a logic-gated, intravenously administered mRNA therapy encoding interleukin-12 (IL-12) designed for solid tumors. It is engineered to selectively activate within the tumor microenvironment to stimulate potent anti-cancer immune response while aiming to minimize systemic toxicity. Preclinical data for STX-001 was presented at meetings of the American Association for Cancer Research and the Society for Immunotherapy of Cancer. Strand filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for STX-001 and initiated a Phase I clinical trial in 2024. The trial is evaluating safety, tolerability, and preliminary efficacy in patients with advanced or metastatic solid tumors. The company's pipeline also includes preclinical programs in oncolytic virotherapy and regenerative medicine.

Partnerships and funding

The company has secured strategic partnerships and significant venture capital financing to advance its platform. A major multi-target collaboration was established with Bristol Myers Squibb in 2024, focusing on the discovery and development of novel programmable mRNA therapeutics for oncology and autoimmune disorders. Earlier research collaborations included work with Lonza Group on manufacturing processes. Key financing rounds include a $52 million Series A round in 2021 co-led by Redmile Group and MPM Capital, with participation from Camford Capital and the Polaris Partners network. In 2023, the company raised a $97 million Series B round led by Fidelity Management & Research Company and Goldman Sachs Asset Management. Other investors include Playground Global, ANRI, and the Beacon Angels.

Leadership and team

The executive leadership is headed by co-founder and Chief Executive Officer Jake Becraft, who holds a PhD in biological engineering from the Massachusetts Institute of Technology. Co-founder Tasuku Kitada serves as Chief Scientific Officer and is an inventor of the core technology. The management team includes veterans from companies such as Moderna, Novartis, and Pfizer. The scientific advisory board features prominent figures in immunology and RNA therapeutics, including Darrell Irvine from MIT and Harvard Medical School, and Geraldine Harriman from HotSpot Therapeutics. The board of directors includes representatives from lead investment firms like MPM Capital and Redmile Group.

Category:Biotechnology companies of the United States Category:Companies based in Boston Category:RNA therapeutics